FDA
-
-
-
-
-
-
-
H.C. Wainwright Downgrades BeyondSpring Inc. (BYSI) to Neutral
-
-
-
-
-
-
-
BeyondSpring (BYSI) call put ratio 1 call to 1.5 puts
-
-
-
-
-
-
-
BeyondSpring (BYSI) Announces Positive Final Phase 3 DUBLIN-3 Data with Plinabulin/Docetaxel Combination versus Docetaxel Alone in 2nd/3rd Line NSCLC Patients with EGFR Wild Type at ESMO
-
-
-
-
-
-
-
BeyondSpring (BYSI) Announces Exclusive Commercialization and Co-development Agreement with Jiangsu Hengrui Pharmaceuticals for Plinabulin in Greater China
-
-
-
-
-
-
-
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
-
-
-
-
-
-
-
BeyondSpring (BYSI) to Present Three Abstracts from PROTECTIVE-2 Phase 3 Trials of Plinabulin at ASCO
-
-
-
-
-
-
-
BeyondSpring Announces Fourth Quarter and Year End 2020 Financial Results and Provides a Corporate Update
-
251,817 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All